Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #2)

被引：0
|
作者：
Ivgy-May, N. [1 ]
Leibensperger, H. [1 ]
Froman, S. [1 ]
Hutzelmann, J. [1 ]
Snavely, D. [1 ]
Snyder, E. [1 ]
Liu, K. [1 ]
Walsh, J.
Roth, T. [2 ]
Michelson, D. [1 ]
Herring, W. J. [1 ]
机构：
[1] Merck, Whitehouse Stn, NJ USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
来源：
JOURNAL OF SLEEP RESEARCH | 2012年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：351 / 352
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1)
    Connor, K.
    Budd, K.
    Snavely, D.
    Liu, K.
    Hutzel-Mann, J.
    Benca, R.
    Krystal, A.
    Roth, T.
    Michelson, D.
    Herring, W. J.
    [J]. JOURNAL OF SLEEP RESEARCH, 2012, 21 : 97 - 97
  • [2] SUVOREXANT: EFFICACY AND SAFETY PROFILE OF A DUAL OREXIN RECEPTOR ANTAGONIST IN TREATING INSOMNIA
    Owen, R. T.
    [J]. DRUGS OF TODAY, 2016, 52 (01) : 29 - 40
  • [3] Efficacy and safety of doxepin 1 and 3 mg in a 3-month trial of elderly adults with chronic primary insomnia
    Roth, T.
    Durrence, H.
    Gotfried, M.
    Hull, S.
    Corser, B.
    Scharf, M.
    Orr, W.
    Buddharaju, V
    Schwartz, H.
    Jochelson, P.
    [J]. SLEEP, 2008, 31 : A230 - A230
  • [4] Clinical Trial Design for Assessment of the Orexin Receptor Antagonist Suvorexant in the Treatment of Insomnia in Patients with Alzheimer's Disease
    Herring, W. Joseph
    Snyder, Ellen
    Bliwise, Donald
    Ancoli-Israel, Sonia
    Budd, Kerry
    Hutzelmann, Jill
    Dam, Tien
    Michelson, David
    [J]. NEUROLOGY, 2017, 88
  • [5] DESIGN OF A CLINICAL TRIAL FOR ASSESSING THE OREXIN RECEPTOR ANTAGONIST SUVOREXANT IN TREATING INSOMNIA IN PATIENTS WITH ALZHEIMER'S DISEASE
    Herring, W. J.
    Snyder, E.
    Bliwise, D.
    Ancoli-Israel, S.
    Budd, K.
    Hutzelmann, J.
    Dam, T.
    Michelson, D.
    Swartz, J.
    [J]. SLEEP MEDICINE, 2017, 40 : E321 - E322
  • [6] Clinical Profile of Suvorexant (MK-4305), an Orexin Receptor Antagonist, in Patients with Primary Insomnia: Results From Phase-3 Trials
    Herring, W. Joseph
    [J]. BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 35S - 35S
  • [7] Orexin receptor antagonism for treatment of insomnia A randomized clinical trial of suvorexant
    Herring, W. Joseph
    Snyder, Ellen
    Budd, Kerry
    Hutzelmann, Jill
    Snavely, Duane
    Liu, Kenneth
    Lines, Christopher
    Roth, Thomas
    Michelson, David
    [J]. NEUROLOGY, 2012, 79 (23) : 2265 - 2274
  • [8] Electroencephalographic Power Spectral Density Profile of the Orexin Receptor Antagonist Suvorexant in Patients with Primary Insomnia and Healthy Subjects
    Ma, Junshui
    Svetnik, Vladimir
    Snyder, Ellen
    Lines, Christopher
    Roth, Thomas
    Herring, W. Joseph
    [J]. SLEEP, 2014, 37 (10) : 1609 - 1619
  • [9] Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial
    Castro, Laura S.
    Otuyama, Leonardo J.
    Fumo-dos-Santos, Cristiane
    Tufik, Sergio
    Poyares, Dalva
    [J]. BRAZILIAN JOURNAL OF PSYCHIATRY, 2020, 42 (02) : 175 - 184
  • [10] LONG TERM SAFETY AND EFFICACY OF SUVOREXANT IN PATIENTS WITH PRIMARY INSOMNIA
    Herring, W. J.
    Snyder, E.
    Paradis, E.
    Liu, M.
    Snavely, D.
    Roth, T.
    Michelson, D.
    [J]. SLEEP, 2012, 35 : A217 - A217
12345